Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer: Why EBRT+ADT remains the gold standard  by Gonzalez-San Segundo, C. et al.
S102 reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S91–S103
Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically local-
ized prostate cancer: Why EBRT+ADT remains the gold standard
C. Gonzalez-San Segundo1, F. Herranz Amo2, G. Ogaya Pinies2, P. Cuesta Álvaro3, F. Calvo Manuel1,
J. Santos-Miranda1
1 Hospital General Universitario Gregorio Maran˜ón, Oncología Radioterápica, Spain
2 Hospital General Universitario Gregorio Maran˜ón, Urología, Spain
3 Universidad Complutense de Madrid, Informatics Department for Research Support, Spain
Purpose. To retrospectively compare results of radical prostatectomy (RP) without adjuvant treatment versus radical external
beam radiotherapy (EBRT) plus androgen deprivation therapy (ADT) for high-risk prostate cancer (PCa) patients.
Methods and materials. Between 1995 and 2008, 305 patients with high-risk PCa were treated at the Urology and Oncology depart-
ments. 140 patients underwent open RP (74% with lymph node dissection) and 165 underwent deﬁnitive EBRT (86% with ADT).
95% received total dose≥74Gy. The 2 groups were homogeneous in terms of cT stage, Gleason score and initial PSA level. Bio-
chemical relapse was deﬁned as a PSA level > 0.4ng/ml for RP patients and nadir + 2 for EBRT. The endpoint selected for analysis
was to compare biochemical recurrence-free survival (bRFS) among groups.
Results. The median follow-up was 74 months [8–184]. The 7-year bRFS rates for RP and EBRT patients were 41.5±4% and 80±4%,
respectively (p=0.00). The disease-speciﬁc survival at 7 years was 91±2% in the surgical group and 95±2% in the EBRT cohort
(p=ns). Seventy-two of 81 patients with BF after surgery (24 of them had persistent high PSA), were treated with EBRT sal-
vage±ADT (51% of the surgical patients). In 22 of 29 patients with BF after EBRT (13% of the irradiated group), salvage treatment
with ADT or chemotherapy was administered. Only 1 patient was treated with local treatment. At the time of analysis, a total
of 30 patients had cancer progression, 20 in the surgery group and 10 in EBRT+ADT group (clinical progression-free survival at
7 years, 85% and 94%, respectively).
Conclusions. Improved outcome with EBRT is observed compared to RP in patients with high-risk PCa regarding bRFS. However,
speciﬁc cancermortalitywas similar between PR and EBRT groups,which emphasizes the efﬁcacy of salvage therapy after surgery.
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Background. Limited information exists on the absolute relationship between testosterone (T) values and clinical outcomes in
prostate cancer (PCa).
Purpose. To evaluate the kinetics of T and the patterns of T recovery after short-term AD (STAD) and long-term AD (LTAD) when
combined with high-dose external-beam radiotherapy (EBRT).
Methods. Between 2005 and 2010, 361 patients with intermediate and high-risk PCa were randomized to receive STAD (4 months)
versus LTAD (28months) combinedwith EBRT as part of amulticentre Spanish prospective randomized phase III trial (DART01/05).
Study endpoints included overall survival, metastasis free survival, disease-free survival and biochemical disease-free survival.
The serum T and PSA data were obtained every 3 months for the ﬁrst 2 years and every six months thereafter. Castration level
was deﬁned as serum T<0.5ng/ml. Time to recovery of serum T level was measured from the last hormone treatment until the
time when normal T values (>1ng/ml) were reached. The median follow-up was 42 months.
Results. Median T basal levels were 4.1ng/ml and 4.0ng/ml for patients in the LTAD and STAD arms, respectively. There was no
signiﬁcant correlation between T basal level and patient age, Gleason score, T stage, risk subgroup and biochemical failure (BF).
The percentage of patients that experienced recovery of T normal values following ADT was 43.8% in LTAD group and 82.7% in
the group treated with STAD. By the Kaplan–Meier method, the median time to recover T normal values was 9.8 months and 22
months (p<0.001) for STAD and LTAD, respectively. The median time to BF was 60.2 months for LTAD (60.6 and 56.9 in patients
with and without recovery of normal T values respectively). For STAD group, the median time to BF was 28 months (28.4 and 18.9
respectively).
